Acute arsenic treatment alters cytochrome P450 expression and arachidonic acid metabolism in lung, liver and kidney of C57Bl/6 mice

Xenobiotica

Volumn 43, Issue 8, 2013, Pages 719-729

  Anwar Mohamed, Anwar ^a   El Sherbeni, Ahmed ^a   Kim, Seok Hee ^a   Elshenawy, Osama H ^a   Althurwi, Hassan N ^a   Zordoky, Beshay N M ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

20 hydroxyeicosatetraenoic acid; Arsenite; Cytochrome hydroxylases; Cytochrome epoxygenases; Epoxyeicosatrienoic acid; Soluble epoxide hydrolase

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; ARSENIC; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2B9; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; KIDNEY; KIDNEY MICROSOME; LIVER; LIVER CYTOSOL; LIVER MICROSOME; LUNG; MALE; METABOLITE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACID; ARSENIC; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; KIDNEY; LIVER; LUNG; MALE; MICE; MICE, INBRED C57BL;

MUS;

EID: 84878449546     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.754113     Document Type: Article

References (53)

1. Aboutabl ME, Zordoky BN, El-Kadi AO. (2009). 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158:1808-19.
2. Anwar-Mohamed A, El-Sherbeni AA, Kim SH, et al. (2012). Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. Xenobiotica 42:1235-47.
3. Anwar-Mohamed A, Zordoky BN, Aboutabl ME, El-Kadi AO. (2010). Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61:410-18.
4. Baldwin WS, Roling JA. (2009). A concentration addition model for the activation of the constitutive androstane receptor by xenobiotic mixtures. Toxicol Sci 107:93-105.
5. Barakat MM, El-Kadi AO, Du Souich P. (2001). L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69:1559-71.
6. Bhattacharyya KK, Brake PB, Eltom SE, et al. (1995). Identification of a rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue-specific pattern of hormonal and aryl hydrocarbon receptor-linked regulation. J Biol Chem 270:11 595-602.
7. Birks EK, Bousamra M, Presberg K, et al. (1997). Human pulmonary arteries dilate to 20-HETE, an endogenous eicosanoid of lung tissue. Am J Physiol 272:L823-9.
8. Choudhary D, Jansson I, Stoilov I, et al. (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32:840-7.
9. Danielson PB. (2002). The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561-97.
10. Das J, Ghosh J, Manna P, et al. (2009). Taurine protects rat testes against NaAsO(2)-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol Lett 187:201-10.
11. Davey JC, Nomikos AP, Wungjiranirun M, et al. (2008). Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. Environ Health Perspect 116:165-72.
12. Elbekai RH, El-Kadi AO. (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564-87.
13. Enayetallah AE, French RA, Thibodeau MS, Grant DF. (2004). Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447-54.
14. Felix K, Manna SK, Wise K, et al. (2005). Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol 19:67-77.
15. Hao CM, Breyer MD. (2007). Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71:1105-15.
16. Hoff U, Lukitsch I, Chaykovska L, et al. (2011). Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79:57-65.
17. Imaoka S, Hashizume T, Funae, Y. (2005). Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet 20:478-84.
18. Imig JD, Navar LG, Roman RJ, et al. (1996). Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7:2364-70.
19. Kaspera R, Totah RA. (2009). Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol 5:757-71.
20. Kimura A, Ishida Y, Hayashi T, et al. (2006). Interferon-gamma plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression. Am J Pathol 169:1118-28.
21. Kohle C, Bock KW. (2009). Coordinate regulation of human drugmetabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689-99.
22. Kumazaki M, Ando H, Sasaki A, et al. (2011). Protective effect of alphalipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats. J Pharmacol Sci 115:244-8.
23. Liu J, Liu Y, Powell DA, et al. (2002). Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 170:55-62.
24. Loot AE, Fleming I. (2011). Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels. J Cardiovasc Pharmacol 57:140-7.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75.
26. Maier KG, Roman RJ. (2001). Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 10:81-7.
27. Malaplate-Armand C, Ferrari L, Masson C, et al. (2003). Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1beta effect and protection by N-acetylcysteine. Toxicol Lett 138:243-51.
28. Manimaran A, Sarkar SN, Sankar P. (2010). Influence of repeated preexposure to arsenic on acetaminophen-induced oxidative stress in liver of male rats. Food Chem Toxicol 48:605-10.
29. Marden NY, Fiala-Beer E, Xiang SH, Murray M. (2003). Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochem J 373:669-80.
30. Mathews V, Desire S, George B, et al. (2006). Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia 20:881-3.
31. Mazumder DN. (2005). Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol 206:169-75.
32. Mitchell SR, Sewer MB, Kardar SS, Morgan ET. (2001). Characterization of CYP4A induction in rat liver by inflammatory stimuli: dependence on sex, strain, and inflammation-evoked hypophagia. Drug Metab Dispos 29:17-22.
33. Moreno C, Maier KG, Hoagland KM, et al. (2001). Abnormal pressurenatriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens 14:90S-7S.
34. Morisseau C, Hammock BD. (2007). Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protocol Toxico 33:1-18.
35. Nilakantan V, Maenpaa C, Jia G, et al. (2008). 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294:F562-70.
36. Patel HV, Kalia K. (2010). Sub-chronic arsenic exposure aggravates nephrotoxicity in experimental diabetic rats. Indian J Exp Biol 48:762-8.
37. Piscaglia F, Knittel T, Kobold D, et al. (1999). Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochem Pharmacol 58:157-65.
38. Powell PK, Wolf I, Jin R, Lasker JM. (1998). Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285:1327-36.
39. Qu W, Rippe RA, Ma J, et al. (1998). Nutritional status modulates rat liver cytochrome P450 arachidonic acid metabolism. Mol Pharmacol 54:504-13.
40. Rahman MM, Ng JC, Naidu R. (2009). Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ Geochem Health 31:189-200.
41. Ramanathan K, Shila S, Kumaran S, Panneerselvam C. (2003). Protective role of ascorbic acid and alpha-tocopherol on arsenic-induced microsomal dysfunctions. Hum Exp Toxicol 22:129-36.
42. Roman RJ. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-85.
43. Sacerdoti D, Gatta A, Mcgiff JC. (2003). Role of cytochrome P450- dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72:51-71.
44. Schwartzman ML, Martasek P, Rios AR, et al. (1990). Cytochrome P450-dependent arachidonic acid metabolism in human kidney. Kidney Int 37:94-9.
45. Theken KN, Deng Y, Kannon MA, et al. (2011). Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos 39:22-9.
46. Umannova L, Zatloukalova J, Machala M, et al. (2007). Tumor necrosis factor-alpha modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver "stem-like" cells. Toxicol Sci 99:79-89.
47. Wu JP, Chang LW, Yao HT, et al. (2009). Involvement of oxidative stress and activation of aryl hydrocarbon receptor in elevation of CYP1A1 expression and activity in lung cells and tissues by arsenic: an in vitro and in vivo study. Toxicol Sci 107:385-93.
48. Yanez L, Carrizales L, Zanatta MT, et al. (1991). Arsenic-cadmium interaction in rats: toxic effects in the heart and tissue metal shifts. Toxicology 67:227-34.
49. Yoshida S, Hirai A, Tamura Y, Yoshida S. (1990). Possible involvement of arachidonic acid metabolites of cytochrome P450 monooxygenase pathway in vasopressin-stimulated glycogenolysis in isolated rat hepatocytes. Arch Biochem Biophys 280:346-51.
50. Yu Z, Ng VY, Su P, et al. (2006). Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther 317:732-8.
51. Zhao X, Feng T, Chen H, et al. (2008). Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity. Basic Clin Pharmacol Toxicol 102:419-25.
52. Zordoky BN, Aboutabl ME, El-Kadi AO. (2008). Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol- induced cardiac hypertrophy in rats. Drug Metab Dispos 36:2277-86.
53. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. (2010). Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38-46.